| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| Targets |
Target: HBV[1].
|
|---|---|
| ln Vitro |
The nucleos(t)ide analogs authorized for the treatment of chronic hepatitis B are all susceptible to resistance markers when it comes to HBV variations that are active against inarigivir (SB 9200)[2].
|
| ln Vivo |
Inarigivir (100 mg/kg/day, i.p.) exhibits anti-HBV action and dramatically lowers viral DNA in the liver. Treatment does not result in a decrease in serum HBV DNA. HBV RNA levels in the liver, HBeAg levels in the blood, and mean titers of HBsAg are unaffected by inarigivir. Based on liver HBV DNA levels, the lowest effective dose is shown to be between 1.6 and 0.5 mg/kg/day[1].
|
| Animal Protocol |
Animal/Disease Models: Mice[1]
Doses: 100 mg/kg. Route of Administration: IP, daily. Experimental Results: Dramatically diminished viral DNA in the liver and shows anti-HBV activity similar ADV positive control. |
| References |
[1]. Iyer RP, et al. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother. 2004 Jun;48(6):2318-20.
[2]. Danni Colledge, et al. The Novel Antiviral Agent Inarigivir Inhibits Both Nucleos(t)ide Analogue and Capsid Assembly Inhibitor Resistant HBV in vitro. |
| Molecular Formula |
C20H29N8O10PS
|
|---|---|
| Molecular Weight |
604.53
|
| Elemental Analysis |
C, 39.74; H, 4.84; N, 18.54; O, 26.47; P, 5.12; S, 5.30
|
| CAS # |
2172788-92-8
|
| Related CAS # |
Inarigivir;475650-36-3
|
| SMILES |
O(C)[C@H]1[C@@H](O[C@H](CO)[C@H]1OP(OC[C@H]2O[C@H](C[C@@H]2O)N3C=4C(N=C3)=C(N)N=CN4)(=O)S)N5C(=O)NC(=O)C=C5.N
|
| InChi Key |
CAUBLFJDYDLFRY-NJCNYLKWSA-N
|
| InChi Code |
InChI=1S/C20H26N7O10PS.H3N/c1-33-16-15(10(5-28)36-19(16)26-3-2-12(30)25-20(26)31)37-38(32,39)34-6-11-9(29)4-13(35-11)27-8-24-14-17(21)22-7-23-18(14)27;/h2-3,7-11,13,15-16,19,28-29H,4-6H2,1H3,(H,32,39)(H2,21,22,23)(H,25,30,31);1H3/t9-,10+,11+,13+,15+,16+,19+,38?;/m0./s1
|
| Chemical Name |
O-(((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl) O-((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-yl) S-hydrogen phosphorothioate, ammonia salt
|
| Synonyms |
Inarigivir ammonium; ORI-9020; ORI 9020; ORI9020; SB-40; SB-9000; SB9000, SB-9000.
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 100 mg/mL (165.42 mM)
DMSO : 100 mg/mL (165.42 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (165.42 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6542 mL | 8.2709 mL | 16.5418 mL | |
| 5 mM | 0.3308 mL | 1.6542 mL | 3.3084 mL | |
| 10 mM | 0.1654 mL | 0.8271 mL | 1.6542 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
